The DIAPH2 Knockout HeLa Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HeLa human cervical adenocarcinoma cell line. This product provides a loss-of-function model for the DIAPH2 gene, which encodes a formin protein critical for actin nucleation and cytoskeletal remodeling. The polyclonal nature of the knockout pool preserves genetic heterogeneity while ensuring robust target-gene disruption across the population, making it suitable for bulk assays and phenotypic screens.
HeLa cells are a widely used epithelial cell line originally established from a cervical adenocarcinoma. They are HPV18-positive and p53-deficient, which contributes to their genomic instability and robust proliferation in culture. This background is particularly relevant for studying cancer cell biology, as it mimics aspects of tumorigenesis and metastasis. The p53 deficiency also abrogates certain DNA damage responses, making HeLa cells a valuable model for investigating proliferation and cytoskeletal dynamics independent of p53-mediated checkpoints.
DIAPH2 is a formin family protein that functions as a key effector of RhoA GTPase signaling. Upon activation by RhoA, DIAPH2 relieves autoinhibition and promotes actin nucleation and polymerization, facilitating the formation of unbranched actin filaments. It also interacts with microtubules via plus-end tracking proteins such as EB1 and APC, contributing to microtubule stabilization. These activities coordinate critical cellular processes including cytokinesis, cell migration, and focal adhesion dynamics. Downstream, DIAPH2-mediated actin assembly engages factors such as anillin and myosin II during contractile ring formation, while its influence on focal adhesions involves vinculin and paxillin. Rac1 signaling and cell cycle-dependent kinases further modulate DIAPH2 activity, integrating cytoskeletal remodeling with proliferative and migratory cues.
In the HeLa cell context, DIAPH2 knockout disrupts the RhoA-directed actin cytoskeleton, providing a platform to dissect mechanisms of cytokinesis failure, altered migration, and invasive behavior. Given HeLa cells?? p53 deficiency and HPV-driven phenotype, this knockout model is particularly useful for studying how DIAPH2 loss impacts metastatic potential independently of apoptosis pathways. Furthermore, because DIAPH2 mutations are linked to autosomal dominant nonsyndromic hearing loss (DFNA1), this model can be adapted to explore cytoskeletal pathologies relevant to sensory hair cell function, though HeLa cells are not of cochlear origin; nevertheless, fundamental cytoskeletal mechanisms can be probed. The polyclonal format ensures that potential off-target effects are diluted, enabling more reliable phenotypic averaging in population-based assays.
Researchers can employ these DIAPH2 knockout HeLa polyclonal cells in a variety of assays, including western blotting and RT-qPCR to confirm gene disruption, immunofluorescence to visualize F-actin and microtubule organization, Boyden chamber migration and invasion assays, and time-lapse microscopy for cytokinesis analysis. Co-immunoprecipitation experiments can validate disrupted interactions with partners such as anillin or myosin II. These cells are also suitable for screening small-molecule modulators of RhoA signaling or actin dynamics. For further technical details or custom inquiries, please contact Ascent Research.
